HIV-1 Vif Triggers Cell Cycle Arrest by Degrading Cellular PPP2R5 Phospho-regulators

Daniel J. Salamango; Terumasa Ikeda; Seyed Arad Moghadasi; Jiayi Wang; Jennifer L. McCann; Artur A. Serebrenik; Diako Ebrahimi; Matthew C. Jarvis; William L. Brown; Reuben S. Harris

doi:10.1016/j.celrep.2019.09.057

HIV-1 Vif Triggers Cell Cycle Arrest by Degrading Cellular PPP2R5 Phospho-regulators

Daniel J. Salamango, Terumasa Ikeda, Seyed Arad Moghadasi, Jiayi Wang, Jennifer L. McCann, Artur A. Serebrenik, Diako Ebrahimi, Matthew C. Jarvis, William L. Brown, Reuben S. Harris

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

HIV-1 Vif hijacks a cellular ubiquitin ligase complex to degrade antiviral APOBEC3 enzymes and PP2A phosphatase regulators (PPP2R5A–E). APOBEC3 counteraction is essential for viral pathogenesis. However, Vif also functions through an unknown mechanism to induce G2 cell cycle arrest. Here, deep mutagenesis is used to define the Vif surface required for PPP2R5 degradation and isolate a panel of separation-of-function mutants (PPP2R5 degradation-deficient and APOBEC3G degradation-proficient). Functional studies with Vif and PPP2R5 mutants were combined to demonstrate that PPP2R5 is, in fact, the target Vif degrades to induce G2 arrest. Pharmacologic and genetic approaches show that direct modulation of PP2A function or depletion of specific PPP2R5 proteins causes an indistinguishable arrest phenotype. Vif function in the cell cycle checkpoint is present in common HIV-1 subtypes worldwide and likely advantageous for viral pathogenesis.

Original language	English (US)
Pages (from-to)	1057-1065.e4
Journal	Cell reports
Volume	29
Issue number	5
DOIs	https://doi.org/10.1016/j.celrep.2019.09.057
State	Published - Oct 29 2019

Bibliographical note

Funding Information:
This work was supported by NIAID R37 AI064046 (to R.S.H.) and a Collaborative Development Project sub-award from NIGMS 2U54GM103368 and NIAID R21 AI138793 (to D.E.). D.J.S. received salary support from the University of Minnesota Craniofacial Research Training (MinnCResT) program (NIH T90 DE022732) and from a NIAID K99/R00 career transition award (K99 AI147811). R.S.H. is the Margaret Harvey Schering Land Grant Chair for Cancer Research, a Distinguished University McKnight Professor, and an Investigator of the Howard Hughes Medical Institute. D.J.S. and R.S.H. led the project. D.J.S. made all DNA constructs and performed most of the experiments. J.L.M. contributed immunoblots, A.A.S. and S.A.M. to knockdown studies, T.I. and J.W. to cell-based studies, D.E. and M.C.J. to sequence comparisons, and W.L.B. to project logistics. D.J.S. and R.S.H. drafted the manuscript, and all authors contributed to revisions. R.S.H. is a co-founder, shareholder, and consultant of ApoGen Biotechnologies Inc.

Funding Information:
This work was supported by NIAID R37 AI064046 (to R.S.H.) and a Collaborative Development Project sub-award from NIGMS 2U54GM103368 and NIAID R21 AI138793 (to D.E.). D.J.S. received salary support from the University of Minnesota Craniofacial Research Training (MinnCResT) program ( NIH T90 DE022732 ) and from a NIAID K99/R00 career transition award ( K99 AI147811 ). R.S.H. is the Margaret Harvey Schering Land Grant Chair for Cancer Research, a Distinguished University McKnight Professor, and an Investigator of the Howard Hughes Medical Institute.

Publisher Copyright:
© 2019 The Author(s)

Keywords

HIV-1
Vif
cell cycle checkpoint
host-pathogen interaction
phosphatase regulation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.celrep.2019.09.057

Find It

Find It at U of M Libraries

Cite this

@article{035c6fd77ac04d13a295d9259e2240c1,

title = "HIV-1 Vif Triggers Cell Cycle Arrest by Degrading Cellular PPP2R5 Phospho-regulators",

abstract = "HIV-1 Vif hijacks a cellular ubiquitin ligase complex to degrade antiviral APOBEC3 enzymes and PP2A phosphatase regulators (PPP2R5A–E). APOBEC3 counteraction is essential for viral pathogenesis. However, Vif also functions through an unknown mechanism to induce G2 cell cycle arrest. Here, deep mutagenesis is used to define the Vif surface required for PPP2R5 degradation and isolate a panel of separation-of-function mutants (PPP2R5 degradation-deficient and APOBEC3G degradation-proficient). Functional studies with Vif and PPP2R5 mutants were combined to demonstrate that PPP2R5 is, in fact, the target Vif degrades to induce G2 arrest. Pharmacologic and genetic approaches show that direct modulation of PP2A function or depletion of specific PPP2R5 proteins causes an indistinguishable arrest phenotype. Vif function in the cell cycle checkpoint is present in common HIV-1 subtypes worldwide and likely advantageous for viral pathogenesis.",

keywords = "HIV-1, Vif, cell cycle checkpoint, host-pathogen interaction, phosphatase regulation",

author = "Salamango, {Daniel J.} and Terumasa Ikeda and Moghadasi, {Seyed Arad} and Jiayi Wang and McCann, {Jennifer L.} and Serebrenik, {Artur A.} and Diako Ebrahimi and Jarvis, {Matthew C.} and Brown, {William L.} and Harris, {Reuben S.}",

note = "Funding Information: This work was supported by NIAID R37 AI064046 (to R.S.H.) and a Collaborative Development Project sub-award from NIGMS 2U54GM103368 and NIAID R21 AI138793 (to D.E.). D.J.S. received salary support from the University of Minnesota Craniofacial Research Training (MinnCResT) program (NIH T90 DE022732) and from a NIAID K99/R00 career transition award (K99 AI147811). R.S.H. is the Margaret Harvey Schering Land Grant Chair for Cancer Research, a Distinguished University McKnight Professor, and an Investigator of the Howard Hughes Medical Institute. D.J.S. and R.S.H. led the project. D.J.S. made all DNA constructs and performed most of the experiments. J.L.M. contributed immunoblots, A.A.S. and S.A.M. to knockdown studies, T.I. and J.W. to cell-based studies, D.E. and M.C.J. to sequence comparisons, and W.L.B. to project logistics. D.J.S. and R.S.H. drafted the manuscript, and all authors contributed to revisions. R.S.H. is a co-founder, shareholder, and consultant of ApoGen Biotechnologies Inc. Funding Information: This work was supported by NIAID R37 AI064046 (to R.S.H.) and a Collaborative Development Project sub-award from NIGMS 2U54GM103368 and NIAID R21 AI138793 (to D.E.). D.J.S. received salary support from the University of Minnesota Craniofacial Research Training (MinnCResT) program ( NIH T90 DE022732 ) and from a NIAID K99/R00 career transition award ( K99 AI147811 ). R.S.H. is the Margaret Harvey Schering Land Grant Chair for Cancer Research, a Distinguished University McKnight Professor, and an Investigator of the Howard Hughes Medical Institute. Publisher Copyright: {\textcopyright} 2019 The Author(s)",

year = "2019",

month = oct,

day = "29",

doi = "10.1016/j.celrep.2019.09.057",

language = "English (US)",

volume = "29",

pages = "1057--1065.e4",

journal = "Cell reports",

issn = "2211-1247",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - HIV-1 Vif Triggers Cell Cycle Arrest by Degrading Cellular PPP2R5 Phospho-regulators

AU - Salamango, Daniel J.

AU - Ikeda, Terumasa

AU - Moghadasi, Seyed Arad

AU - Wang, Jiayi

AU - McCann, Jennifer L.

AU - Serebrenik, Artur A.

AU - Ebrahimi, Diako

AU - Jarvis, Matthew C.

AU - Brown, William L.

AU - Harris, Reuben S.

N1 - Funding Information: This work was supported by NIAID R37 AI064046 (to R.S.H.) and a Collaborative Development Project sub-award from NIGMS 2U54GM103368 and NIAID R21 AI138793 (to D.E.). D.J.S. received salary support from the University of Minnesota Craniofacial Research Training (MinnCResT) program (NIH T90 DE022732) and from a NIAID K99/R00 career transition award (K99 AI147811). R.S.H. is the Margaret Harvey Schering Land Grant Chair for Cancer Research, a Distinguished University McKnight Professor, and an Investigator of the Howard Hughes Medical Institute. D.J.S. and R.S.H. led the project. D.J.S. made all DNA constructs and performed most of the experiments. J.L.M. contributed immunoblots, A.A.S. and S.A.M. to knockdown studies, T.I. and J.W. to cell-based studies, D.E. and M.C.J. to sequence comparisons, and W.L.B. to project logistics. D.J.S. and R.S.H. drafted the manuscript, and all authors contributed to revisions. R.S.H. is a co-founder, shareholder, and consultant of ApoGen Biotechnologies Inc. Funding Information: This work was supported by NIAID R37 AI064046 (to R.S.H.) and a Collaborative Development Project sub-award from NIGMS 2U54GM103368 and NIAID R21 AI138793 (to D.E.). D.J.S. received salary support from the University of Minnesota Craniofacial Research Training (MinnCResT) program ( NIH T90 DE022732 ) and from a NIAID K99/R00 career transition award ( K99 AI147811 ). R.S.H. is the Margaret Harvey Schering Land Grant Chair for Cancer Research, a Distinguished University McKnight Professor, and an Investigator of the Howard Hughes Medical Institute. Publisher Copyright: © 2019 The Author(s)

PY - 2019/10/29

Y1 - 2019/10/29

N2 - HIV-1 Vif hijacks a cellular ubiquitin ligase complex to degrade antiviral APOBEC3 enzymes and PP2A phosphatase regulators (PPP2R5A–E). APOBEC3 counteraction is essential for viral pathogenesis. However, Vif also functions through an unknown mechanism to induce G2 cell cycle arrest. Here, deep mutagenesis is used to define the Vif surface required for PPP2R5 degradation and isolate a panel of separation-of-function mutants (PPP2R5 degradation-deficient and APOBEC3G degradation-proficient). Functional studies with Vif and PPP2R5 mutants were combined to demonstrate that PPP2R5 is, in fact, the target Vif degrades to induce G2 arrest. Pharmacologic and genetic approaches show that direct modulation of PP2A function or depletion of specific PPP2R5 proteins causes an indistinguishable arrest phenotype. Vif function in the cell cycle checkpoint is present in common HIV-1 subtypes worldwide and likely advantageous for viral pathogenesis.

AB - HIV-1 Vif hijacks a cellular ubiquitin ligase complex to degrade antiviral APOBEC3 enzymes and PP2A phosphatase regulators (PPP2R5A–E). APOBEC3 counteraction is essential for viral pathogenesis. However, Vif also functions through an unknown mechanism to induce G2 cell cycle arrest. Here, deep mutagenesis is used to define the Vif surface required for PPP2R5 degradation and isolate a panel of separation-of-function mutants (PPP2R5 degradation-deficient and APOBEC3G degradation-proficient). Functional studies with Vif and PPP2R5 mutants were combined to demonstrate that PPP2R5 is, in fact, the target Vif degrades to induce G2 arrest. Pharmacologic and genetic approaches show that direct modulation of PP2A function or depletion of specific PPP2R5 proteins causes an indistinguishable arrest phenotype. Vif function in the cell cycle checkpoint is present in common HIV-1 subtypes worldwide and likely advantageous for viral pathogenesis.

KW - HIV-1

KW - Vif

KW - cell cycle checkpoint

KW - host-pathogen interaction

KW - phosphatase regulation

UR - http://www.scopus.com/inward/record.url?scp=85073737663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073737663&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2019.09.057

DO - 10.1016/j.celrep.2019.09.057

M3 - Article

C2 - 31665623

AN - SCOPUS:85073737663

SN - 2211-1247

VL - 29

SP - 1057-1065.e4

JO - Cell reports

JF - Cell reports

IS - 5

ER -

HIV-1 Vif Triggers Cell Cycle Arrest by Degrading Cellular PPP2R5 Phospho-regulators

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this